Interventional cardiology in a whole new light

Open menu

News & Events

OPSENS ANNOUNCES DEPARTURE OF CFO

5 May 2017

OPSENS ANNOUNCES DEPARTURE OF CFO Quebec City, Quebec, May 05, 2017 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) has today announced the departure of Mr. Thierry Dumas, Chief Financial Officer and Corporate Secretary. Mr. Dumas will leave the Company on May 12, 2017. Mr. Louis Laflamme, Opsens’ current President and Chief Executive Officer, will assume…

Read more

VISIT OPSENS MEDICAL AT THE SCAI 2017 SCIENTIFIC SESSIONS

25 April 2017

Learn more about OptoWire Deux at booth #615 at the SCAI 2017 Scientific Sessions, and attend the Opsens sponsored complimentary dinner educational symposium, “Applying Advanced Physiology Technology in the New PCI Era”. This program is geared toward the interventionalist seeking to better understand complex PCI in the modern era. Presentations will focus on the latest…

Read more

OPSENS REPORTS Q2 2017 RESULTS – QUARTERLY CONSOLIDATED REVENUES UP 75% TO $4.8 MILLION

19 April 2017

OPSENS REPORTS Q2 2017 RESULTS – QUARTERLY CONSOLIDATED REVENUES UP 75% TO $4.8 MILLION Quebec City, Quebec, April 19, 2017 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) today reported its results for the second quarter ended February 28, 2017. Highlights Growth in sales of products to measure Fractional Flow Reserve (“FFR”) in Q2 2017 at…

Read more

OPSENS ANNOUNCES GRADUATION TO TSX

28 February 2017

Quebec City, Quebec, February 28, 2017 – Opsens Inc. (“Opsens” or the “Company”) (TSXV:OPS) (OTCQX:OPSSF) is pleased to announce that it has received final approval for the listing of the Corporation’s common shares (the “Common Shares”) on the Toronto Stock Exchange (“TSX”). The Common Shares will commence trading on the TSX effective as of the…

Read more

OPSENS REPORTS Q1 2017 RESULTS – FOCUSED EXECUTION LEADS TO RECORD QUARTERLY REVENUES

26 January 2017

Quebec City, Quebec, January 26, 2017 – Opsens Inc. (“Opsens” or the “Company”) (TSXV:OPS) (OTCQX:OPSSF) today reported its results for the first quarter ended November 30, 2016. Highlights Fractional Flow Reserve (“FFR”) revenues were $2,743,000 compared with $893,000 in the same quarter last year, an increase of $1,850,000 or 207%; Consolidated revenues for Q1 2017…

Read more

OPSENS INC. COMPLETES A $14.95 MILLION EQUITY FINANCING BY WAY OF PROSPECTUS

8 December 2016

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OPSENS INC. COMPLETES A $14.95 MILLION EQUITY FINANCING BY WAY OF PROSPECTUS Quebec City, Quebec, December 8, 2016 – Opsens Inc. (“Opsens” or the “Corporation”) (TSXV: OPS) (OTCQX: OPSSF) is pleased to announce that it has closed its previously announced short form…

Read more

OPSENS ANNOUNCES UPSIZE TO AND PROVIDES ADDITIONAL DETAILS REGARDING ITS PROPOSED EQUITY FINANCING

23 November 2016

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OPSENS INC. ANNOUNCES UPSIZE TO AND provides additional details regarding its proposed equity financing Quebec City, Quebec, November 23, 2016 – Opsens Inc. (“Opsens” or the “Corporation”) (TSXV:OPS) (OTCQX:OPSSF) is pleased to announce that it has amended the terms of its…

Read more

Opsens Announces Equity Financing

23 November 2016

      NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Opsens Announces Equity Financing Quebec City, Quebec, November 22, 2016 – Opsens Inc. (“Opsens”) (TSXV:OPS) (OTCQX:OPSSF) is pleased to announce that it has filed a preliminary short form prospectus in connection with a proposed marketed offering of common…

Read more

OPSENS REPORTS RESULTS FOR 2016 – RECORD TOTAL REVENUES DRIVEN BY TENFOLD INCREASE IN FFR SALES

16 November 2016

Quebec City, Quebec, November 16, 2016 – Opsens Inc. (“Opsens”) (TSXV:OPS) (OTCQX:OPSSF) today reported its results for the year ended August 31, 2016. Highlights The OptoWire II, Opsens’ guidewire to measure Fractional Flow Reserve (“FFR”) has been authorized for sale in the U.S., Europe, Japan and Canada; FFR product sales FFR revenues were $2.1 million…

Read more

OPSENS RECEIVES 510(K) CLEARANCE FOR THE OPTOMONITOR II PROVIDING EXTENDED INDICATION

26 September 2016

OPSENS RECEIVES 510(K) CLEARANCE FOR THE OPTOMONITOR II PROVIDING EXTENDED INDICATION Quebec City, Quebec, September 26, 2016 – Opsens Inc. (“Opsens” or the “Company”) (TSXV:OPS) (OTCQX:OPSSF) announces 510(k) clearance from the U.S. Food and Drug Administration (“FDA“) for the OptoMonitor II, a new multimodality monitor combining the ability to measure Fractional Flow Reserve (“FFR”) along…

Read more